Balancing Innovation: India’s Views for Pharmaceuticals in the Efta Trade Deal
IIPRD
APRIL 2, 2024
[iii] Understanding the intricacies of the negotiations thus, becomes even more critical when we consider the actualities of the pharmaceutical industry. The implementation of TRIPS-Plus provisions can also readily facilitate the emergence of monopoly power for brand-name pharmaceutical companies. [v]
Let's personalize your content